Meisterernst Rechtsanwälte
Client SatisfactionWe are only able to display limited information for this firm. We display more complete information for all of the following firms:
Meisterernst Rechtsanwälte places a dual focus on pharmaceutical and food law and advises clients from the pharmaceutical and medical device sectors on competition law and pharmaceutical advertising law issues, including litigation. The latter also includes landmark proceedings, where practice head Christian Tillmanns frequently takes the lead. Recent instructions include advising pharmaceutical companies on price negotiations and cost-benefit assessments. Markus Fuderer was appointed partner in January 2023; he is well versed in matters pertaining to technology, including software solutions and AI, as well as cybersecurity and data protection.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
- 'Dr. Christian Tillmanns and Sylvia Braun represented us extremely competently and successfully in and out of court.'
- 'In addition to the advertising law and procedural expertise and experience of the team led by Dr. Christian Tillmann's breadth of consulting practice should also be emphasized.'
Abbreviated data is displayed for this firm.
Key clients
- Alnylam Germany GmbH / Alnylam Switzerland GmbH
- Amicus Therpeutics GmbH
Abbreviated data is displayed for this firm.
Work highlights
- Supporting the preparation of the market entry of new products for the biopharmaceutical company Alnylam, headquartered in the USA; In addition, ongoing advice and representation on pharmaceutical advertising law.
- Ongoing advice to Amicus Therapeutics GmbH on approval and contract law, on clinical studies and cooperation agreements with medical centers, on sales and advertising law as well as on compliance; recently also provided advice and representation in connection with AMNOG proceedings in price negotiations on reimbursement contributions with the National Association of Statutory Health Insurance Funds following the extension of approval for medicinal products; also advice on benefit assessment matters with the Federal Joint Committee.
Abbreviated data is displayed for this firm.